Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2022)
15 slides from Genetic Signatures's shareholder meeting presentation, Nov 16, 2022
Slide 1: Chairman's Address and CEO Presentation at Annual General Meeting
ASX Code: GSS 16 November 2022 Chairman’s Address and CEO Presentation For personal use only at Annual General Meeting Genetic Signatures Limited (ASX:GSS) is pleased to release the Annual General Meeting Chairman’s Address and CEO presentation. Chairman’s Address: Good morning, and welcome to the G
Slide 2: Chairman's Address (continued)
While the future course and consequences of the COVID pandemic remain unknowable, Genetic Signatures expects to continue to play an important role in the management of future outbreaks. One of the significant benefits of Genetic Signatures’ 3base approach is it is less susceptible to the genetic cha
Slide 3: 2022 Annual General Meeting
For personal use only 2022 Annual General Meeting 16 November 2022
Slide 4: Disclaimer
2022 AnnualDOCUMENT General Meeting TITLE Disclaimer 16 November October 2022 2021 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written For personal use only materials/slides fo
Slide 5: Investment highlights
Investment highlights 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 Proprietary 3base® technology platform that provides a revolutionary For personal use only approach for molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiple
Slide 6: Company Snapshot
2022 AnnualDOCUMENT General Meeting TITLE Company Snapshot 16 November October 2022 2021 For personal use only Financial information Share price Volume (m) 2.00 4.00 Share price (15-Nov-22) A$0.70 1.80 3.50 1.60 Shares on issue 143.4m 1.40 3.00 1.20 2.50 Market capitalisation A$100.4m 1.00 2.00 0.80
Slide 7: Track record of continued, strong revenue growth
Track record of continued, strong revenue growth 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 Sales Revenue (A$m) FY22 sales revenue of $35.4 million For personal use only • 25% growth yoy, 89% 4yr CAGR • Q1 FY23 sales up 16% from preceding quarter 35.4 Growing contributio
Slide 8: FY22 Financial Summary – Cashflow
FY22 Financial Summary – Cashflow 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 A'000s FY22 Planned investment in growth opportunities For personal use only Receipts from customers 39,405 Funded from existing cash and anticipated future cash Payments to suppliers and employ
Slide 9: Robust pipeline with multiple products cleared for sale
Robust pipeline with multiple products cleared for sale 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 For personal use only DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 7
Slide 10: Enteric Protozoan kit will provide entry to North America
Enteric Protozoan kit will provide entry to North America DOCUMENT 2022 Annual General TITLE Meeting October2022 16 November 2021 High need for Enteric Protozoan Kit For personal use only • 5.5 million tests conducted in the US pa; • Primarily culture/microscopy: slow, labour intensive, unreliable;
Slide 11: Recent Events
Recent Events 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 For personal use only US FDA clinical trial recruitment completed • Targeting 4Q CY2022 application for clearance 3base® kit for antimicrobial resistance shows high detection rate • Independent study1 showed excell
Slide 12: Growth initiatives
Growth initiatives 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 For personal use only Leverage experience in Australian market to grow international sales • Europe – drive adoption of other 3base® products; • US – build 3base® franchise once Protozoan Detection Kit is clea
Slide 13: New products and instruments
New products and instruments 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 For personal use only Expand available EasyScreen™ Syndromic Kits • 3 kits research use only (RUO) – tropical diseases, MMR & meningitis; • Other kits in development (tick-borne, skin infections, etc
Slide 14: Upcoming milestones
Upcoming milestones – 12 months 2022 AnnualDOCUMENT General Meeting 16 November TITLE October 2022 2021 For personal use only US Enteric Protozoan Kit • File 510(k) application by end of CY2022; • Launch product once clearance is granted. Increase sales and presence in UK and European markets • Cont
Slide 15: For personal use only
For personal use only 13
Genetic Signatures — Shareholder Meeting (November 2022) on 6ix